Tianjin Zhongxin Pharmaceutical Group Corp Ltd - Asset Resilience Ratio
Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329) has an Asset Resilience Ratio of 5.92% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Tianjin Zhongxin Pharmaceutical Group Co debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2024)
This chart shows how Tianjin Zhongxin Pharmaceutical Group Corp Ltd's Asset Resilience Ratio has changed over time. See shareholders equity of Tianjin Zhongxin Pharmaceutical Group Co for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Tianjin Zhongxin Pharmaceutical Group Corp Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Tianjin Zhongxin Pharmaceutical Group Co worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥685.28 Million | 5.92% |
| Total Liquid Assets | CN¥685.28 Million | 5.92% |
Asset Resilience Insights
- Limited Liquidity: Tianjin Zhongxin Pharmaceutical Group Corp Ltd maintains only 5.92% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Tianjin Zhongxin Pharmaceutical Group Corp Ltd Industry Peers by Asset Resilience Ratio
Compare Tianjin Zhongxin Pharmaceutical Group Corp Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521 |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE |
Drug Manufacturers - Specialty & Generic | 1.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 2.69% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 20.24% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for Tianjin Zhongxin Pharmaceutical Group Corp Ltd (2000–2024)
The table below shows the annual Asset Resilience Ratio data for Tianjin Zhongxin Pharmaceutical Group Corp Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 9.29% | CN¥1.00 Billion ≈ $146.34 Million |
CN¥10.77 Billion ≈ $1.58 Billion |
+9.09pp |
| 2023-12-31 | 0.20% | CN¥20.31 Million ≈ $2.97 Million |
CN¥10.23 Billion ≈ $1.50 Billion |
-0.36pp |
| 2019-12-31 | 0.55% | CN¥43.52 Million ≈ $6.37 Million |
CN¥7.84 Billion ≈ $1.15 Billion |
-0.20pp |
| 2018-12-31 | 0.75% | CN¥53.31 Million ≈ $7.80 Million |
CN¥7.11 Billion ≈ $1.04 Billion |
-0.77pp |
| 2017-12-31 | 1.52% | CN¥100.50 Million ≈ $14.71 Million |
CN¥6.62 Billion ≈ $968.98 Million |
+1.51pp |
| 2016-12-31 | 0.01% | CN¥660.00K ≈ $96.58K |
CN¥6.36 Billion ≈ $930.77 Million |
-0.01pp |
| 2015-12-31 | 0.02% | CN¥1.49 Million ≈ $218.62K |
CN¥6.07 Billion ≈ $888.07 Million |
-0.95pp |
| 2013-12-31 | 0.97% | CN¥51.25 Million ≈ $7.50 Million |
CN¥5.26 Billion ≈ $770.04 Million |
+0.81pp |
| 2005-12-31 | 0.16% | CN¥6.54 Million ≈ $957.01K |
CN¥4.06 Billion ≈ $593.48 Million |
-0.04pp |
| 2004-12-31 | 0.20% | CN¥8.00 Million ≈ $1.17 Million |
CN¥3.91 Billion ≈ $572.63 Million |
-1.13pp |
| 2003-12-31 | 1.34% | CN¥50.70 Million ≈ $7.42 Million |
CN¥3.80 Billion ≈ $555.64 Million |
+1.30pp |
| 2002-12-31 | 0.04% | CN¥1.14 Million ≈ $166.38K |
CN¥3.01 Billion ≈ $440.18 Million |
+0.02pp |
| 2001-12-31 | 0.02% | CN¥424.00K ≈ $62.04K |
CN¥2.72 Billion ≈ $397.98 Million |
-5.00pp |
| 2000-12-31 | 5.02% | CN¥126.86 Million ≈ $18.56 Million |
CN¥2.53 Billion ≈ $369.87 Million |
-- |
About Tianjin Zhongxin Pharmaceutical Group Corp Ltd
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmologic… Read more